Market Summary
USD33.10-0.89
Delayedas of 21 Sep 2023, 12:36 pm-2.62%
NTLA Alerts
NTLA Stock Price
NTLA RSI Chart
NTLA Valuation
NTLA Price/Sales (Trailing)
NTLA Profitability
NTLA Fundamentals
NTLA Revenue
NTLA Earnings
Price Action
52 Week Range
32.4463.12
(Low)(High)
Last 7 days
-4.2%
Last 30 days
-10.1%
Last 90 days
-19.0%
Trailing 12 Months
-45.6%
NTLA Financial Health
NTLA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for NTLA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-07-31 | Bhanji Muna | sold | -11,217 | 42.33 | -265 | - |
2023-07-06 | Bhanji Muna | sold | -73,373 | 39.3 | -1,867 | - |
2023-07-03 | Clark Eliana | sold | -14,583 | 40.51 | -360 | evp, chief technical officer |
2023-06-20 | Clark Eliana | acquired | 61,350 | 12.27 | 5,000 | evp, chief technical officer |
2023-06-20 | Clark Eliana | sold | -225,000 | 45.00 | -5,000 | evp, chief technical officer |
2023-06-14 | CHASE WILLIAM J | acquired | - | - | 1,673 | - |
2023-06-14 | Crowley John F | acquired | - | - | 4,425 | - |
2023-06-14 | Bhanji Muna | acquired | - | - | 4,425 | - |
2023-06-14 | GOODMAN JESSE | acquired | - | - | 4,425 | - |
2023-06-14 | Keresty Georgia | acquired | - | - | 4,425 | - |
Which funds bought or sold NTLA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 63.00 | 734 | -% |
2023-09-07 | Triatomic Management LP | sold off | -100 | -372,700 | - | -% |
2023-09-06 | Deep Track Capital, LP | added | 18.58 | 7,811,540 | 34,069,500 | 1.58% |
2023-09-01 | Orchard Capital Management, LLC | new | - | 6,490,340 | 6,490,340 | 2.18% |
2023-08-23 | WOLVERINE TRADING, LLC | new | - | 264,541 | 264,541 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 24.64 | 93,545 | 350,708 | -% |
2023-08-21 | VitalStone Financial, LLC | new | - | - | - | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 6.45 | 571,299 | 4,039,420 | 0.01% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -6.2 | 23,176 | 817,639 | -% |
2023-08-16 | Nuveen Asset Management, LLC | reduced | -52.63 | -18,999,900 | 20,440,100 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
NTLA Alerts
Schedule 13G FIlings of Intellia Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.28% | 7,810,226 | SC 13G/A | |
| Jan 25, 2023 | blackrock inc. | 8.7% | 7,254,921 | SC 13G | |
| Feb 14, 2022 | nikko asset management americas, inc. | 3.70% | 2,753,903 | SC 13G/A | |
| Feb 11, 2022 | regeneron pharmaceuticals, inc. | 4.98% | 3,702,995 | SC 13G/A | |
| Feb 09, 2022 | ark investment management llc | 10.64% | 7,916,882 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G | |
| Feb 04, 2022 | sumitomo mitsui trust holdings, inc. | 3.70% | 2,753,903 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.6% | 5,620,376 | SC 13G/A | |
| Nov 26, 2021 | ark investment management llc | 10.40% | 7,642,452 | SC 13G/A |
Recent SEC filings of Intellia Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 03, 2023 | 10-Q | Quarterly Report | |
| Aug 03, 2023 | 8-K | Current Report | |
| Aug 02, 2023 | 4 | Insider Trading | |
| Jul 31, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 10, 2023 | 4 | Insider Trading | |
| Jul 06, 2023 | 144 | Notice of Insider Sale Intent | |
| Jul 06, 2023 | 4 | Insider Trading | |
| Jun 22, 2023 | 4 | Insider Trading | |
| Jun 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Jun 16, 2023 | 8-K | Current Report |
Peers (Alternatives to Intellia Therapeutics)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
ABBV | 271.4B | 56.0B | 2.30% | 9.45% | 31.25 | 4.84 | -2.31% | -31.27% |
BGNE | 265.4B | 1.8B | -1.67% | 25.43% | -153.19 | 146.56 | 69.45% | 14.65% |
VRTX | 90.8B | 9.5B | 0.45% | 22.78% | 26.99 | 9.56 | 13.83% | 5.33% |
REGN | 89.0B | 12.7B | -1.51% | 18.09% | 20.7 | 7.02 | -10.94% | -24.40% |
ALNY | 21.9B | 1.2B | -7.00% | -17.21% | -20.61 | 17.72 | 39.94% | -8.44% |
SRPT | 11.0B | 1.0B | 3.70% | 3.57% | -12.12 | 10.97 | 20.15% | -79.16% |
UTHR | 10.5B | 2.1B | -3.12% | 8.08% | 12.05 | 4.98 | 18.01% | 38.16% |
| MID-CAP | ||||||||
BPMC | 3.1B | 225.6M | 0.04% | -28.00% | -5.53 | 13.59 | -2.11% | 21.02% |
MDGL | 3.0B | - | -10.01% | 147.80% | -9.03 | - | - | -28.88% |
RARE | 2.6B | 402.9M | -2.14% | -20.15% | -3.59 | 6.42 | 20.50% | -42.46% |
MRTX | 1.9B | 27.2M | -14.18% | -57.07% | -2.57 | 69.63 | - | -14.43% |
| SMALL-CAP | ||||||||
CYTK | 3.1B | - | -2.94% | -39.70% | -7.31 | 33.28 | 34.30% | -149.91% |
CPRX | 1.3B | 302.9M | -16.58% | -4.84% | 11.23 | 4.28 | 77.72% | 112.02% |
MGNX | 281.2M | 152.5M | -11.67% | 38.41% | 37.75 | 1.84 | 127.84% | 103.41% |
CRBP | 29.9M | - | 1.35% | 3552.08% | -0.65 | - | - | -31.51% |
Intellia Therapeutics News
Returns for NTLA
Cumulative Returns on NTLA
8.9%
7-Year Cumulative Returns
4.9%
5-Year Cumulative Returns
13.1%
3-Year Cumulative Returns
Risks for NTLA
What is the probability of a big loss on NTLA?
100%
Probability that Intellia Therapeutics stock will be more than 20% underwater in next one year
95%
Probability that Intellia Therapeutics stock will be more than 30% underwater in next one year.
71.5%
Probability that Intellia Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does NTLA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Intellia Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.8% | 53,039,000 | 53,475,000 | 52,121,000 | 51,402,000 | 45,340,000 | 37,860,000 | 33,053,000 | 26,794,000 | 41,810,000 | 51,523,000 | 57,994,000 | 62,335,000 | 50,731,000 | 45,586,000 | 43,103,000 | 40,047,000 | 36,839,000 | 33,398,000 | 30,434,000 | 29,222,000 | 29,131,000 |
| S&GA Expenses | 8.9% | 103,871,000 | 95,351,000 | 90,306,000 | 88,788,000 | 85,354,000 | 79,905,000 | 71,096,000 | 59,751,000 | 51,606,000 | 46,449,000 | 44,169,000 | 42,382,000 | 40,247,000 | 41,839,000 | 41,058,000 | 40,790,000 | 40,629,000 | 35,316,000 | 32,189,000 | 33,694,000 | 31,135,000 |
| R&D Expenses | 6.5% | 409,077,000 | 384,000,000 | 419,979,000 | 391,106,000 | 354,941,000 | 323,626,000 | 229,807,000 | 196,877,000 | 176,147,000 | 155,034,000 | 150,408,000 | 143,908,000 | 131,665,000 | 119,354,000 | 108,413,000 | 96,600,000 | 92,324,000 | 90,331,000 | 89,115,000 | 90,367,000 | 84,611,000 |
| EBITDA | - | - | - | - | - | - | - | -60,652,000 | -60,941,000 | -61,125,000 | -61,193,000 | -61,243,000 | -61,255,000 | -61,474,000 | -61,701,000 | -61,943,000 | -62,295,000 | -62,526,000 | -62,792,000 | - | - | - |
| EBITDA Margin | - | - | - | - | - | - | - | -1.83 | -2.27 | -1.46 | -1.19 | -1.06 | -0.98 | -1.21 | -1.35 | -1.44 | -1.56 | -1.70 | -1.88 | - | - | - |
| EBT Margin | - | - | - | - | - | - | - | -2.04 | -2.52 | -1.62 | -1.31 | -1.16 | -1.08 | -1.33 | -1.48 | -1.57 | -1.69 | -1.83 | -2.02 | - | - | - |
| Net Income | -5.3% | -453,443,000 | -430,440,000 | -474,186,000 | -442,016,000 | -400,431,000 | -368,559,000 | -267,892,000 | -228,847,000 | -185,043,000 | -148,630,000 | -134,231,000 | -120,315,000 | -116,109,000 | -109,399,000 | -99,533,000 | -90,323,000 | -89,391,000 | -85,927,000 | -85,343,000 | -90,240,000 | -82,894,000 |
| Net Income Margin | 100.0% | - | -8.05 | -9.10 | -8.60 | -8.83 | -9.73 | -8.10 | -8.54 | -4.43 | -2.88 | -2.31 | -1.93 | -2.29 | -2.40 | -2.31 | - | - | - | - | - | - |
| Free Cashflow | 100.0% | - | -378,775,000 | -346,845,000 | -310,583,000 | -297,380,000 | -264,228,000 | -237,786,000 | -221,499,000 | -181,195,000 | -68,895,000 | -53,497,000 | -43,499,000 | -41,439,000 | -126,438,000 | -110,034,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -6.7% | 1,323 | 1,418 | 1,520 | 1,084 | 1,110 | 1,203 | 1,294 | 1,335 | 672 | 717 | 676 | 459 | 491 | 315 | 334 | 347 | 352 | 344 | 347 | 321 | 340 |
| Current Assets | -2.5% | 940 | 964 | 1,217 | 859 | 895 | 875 | 769 | 815 | 549 | 601 | 617 | 416 | 446 | 270 | 289 | 296 | 307 | 304 | 325 | 299 | 318 |
| Cash Equivalents | -41.6% | 172 | 294 | 524 | 141 | 148 | 133 | 123 | 335 | 130 | 142 | 160 | 180 | 362 | 81.00 | 57.00 | 38.00 | 49.00 | 47.00 | 59.00 | 293 | 306 |
| Net PPE | 5.0% | 33.00 | 32.00 | 28.00 | 27.00 | 26.00 | 24.00 | 21.00 | 20.00 | 19.00 | 16.00 | 16.00 | 16.00 | 16.00 | 17.00 | 18.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 | 17.00 |
| Current Liabilities | -3.4% | 100 | 103 | 127 | 131 | 124 | 126 | 126 | 98.00 | 74.00 | 61.00 | 64.00 | 56.00 | 59.00 | 35.00 | 36.00 | 38.00 | 38.00 | 39.00 | 41.00 | 26.00 | 25.00 |
| Shareholder's Equity | -7.2% | 1,105 | 1,191 | 1,236 | 825 | 881 | 954 | 1,040 | 1,107 | 495 | 546 | 527 | 330 | 352 | 248 | 270 | 276 | 277 | 264 | 278 | 263 | 279 |
| Retained Earnings | -9.7% | -1,403 | -1,280 | -1,177 | -1,063 | -950 | -849 | -703 | -621 | -550 | -481 | -435 | -392 | -365 | -332 | -300 | -272 | -248 | -223 | -201 | -181 | -159 |
| Additional Paid-In Capital | 1.6% | 2,513 | 2,474 | 2,420 | 1,898 | 1,841 | 1,812 | 1,746 | 1,729 | 1,045 | 1,027 | 962 | 723 | 717 | 580 | 570 | 548 | 526 | 488 | 479 | 445 | 439 |
| Shares Outstanding | 0.3% | 88.00 | 88.00 | 87.00 | 77.00 | 76.00 | 75.00 | 74.00 | 74.00 | 68.00 | 67.00 | 66.00 | 54.00 | 52.00 | 50.00 | 50.00 | 49.00 | 46.00 | 45.00 | 43.00 | 43.00 | 43.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -1.4% | -368 | -362 | -333 | -298 | -284 | -252 | -225 | -210 | -174 | -63.74 | -49.91 | -38.35 | -35.24 | -120 | -103 | -83.12 | -70.12 | -64.94 | -61.26 | -74.03 | -78.46 |
| Share Based Compensation | 13.3% | 113 | 100 | 91.00 | 81.00 | 72.00 | 59.00 | 47.00 | 38.00 | 28.00 | 22.00 | 20.00 | 17.00 | 15.00 | 15.00 | 15.00 | 16.00 | 17.00 | 18.00 | 17.00 | 20.00 | 19.00 |
| Cashflow From Investing | -1380.0% | -139 | -9.41 | 160 | 31.00 | -415 | -477 | -550 | -602 | -357 | -297 | -214 | 24.00 | 147 | 77.00 | 25.00 | -258 | -229 | -253 | -260 | -7.16 | -7.41 |
| Cashflow From Financing | -0.6% | 534 | 538 | 583 | 79.00 | 724 | 725 | 737 | 969 | 300 | 426 | 372 | 157 | 203 | 77.00 | 76.00 | 87.00 | 43.00 | 37.00 | 40.00 | 152 | 150 |
NTLA Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Collaboration revenue | $ 13,594 | $ 14,030 | $ 26,200 | $ 25,282 |
| Type of Revenue [Extensible List] | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember | us-gaap:LicenseAndServiceMember |
| Operating expenses: | ||||
| Research and development | $ 115,276 | $ 90,199 | $ 212,392 | $ 223,294 |
| General and administrative | 30,652 | 22,132 | 58,100 | 44,535 |
| Total operating expenses | 145,928 | 112,331 | 270,492 | 267,829 |
| Operating loss | (132,334) | (98,301) | (244,292) | (242,547) |
| Other income (expense), net: | ||||
| Interest income | 12,653 | 703 | 24,633 | 1,243 |
| Loss from equity method investment | (4,000) | (3,252) | (7,048) | (5,997) |
| Change in fair value of contingent consideration | 0 | 172 | (100) | (249) |
| Total other income (expense), net | 8,653 | (2,377) | 17,485 | (5,003) |
| Net loss | $ (123,681) | $ (100,678) | $ (226,807) | $ (247,550) |
| Net loss per share, basic | $ (1.4) | $ (1.33) | $ (2.58) | $ (3.29) |
| Net loss per share, diluted | $ (1.4) | $ (1.33) | $ (2.58) | $ (3.29) |
| Weighted average shares outstanding, basic | 88,185 | 75,823 | 87,979 | 75,282 |
| Weighted average shares outstanding, diluted | 88,185 | 75,823 | 87,979 | 75,282 |
| Other comprehensive loss: | ||||
| Unrealized (loss) gain on marketable securities | $ (1,482) | $ (932) | $ 1,507 | $ (6,060) |
| Other comprehensive gain (loss) from equity method investment | 292 | (560) | 2,086 | (862) |
| Comprehensive loss | $ (124,871) | $ (102,170) | $ (223,214) | $ (254,472) |
NTLA Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 171,806 | $ 523,506 |
| Marketable securities | 736,268 | 669,116 |
| Accounts receivable ($0 and $0.3 million, respectively, from related party) | 5,056 | 3,768 |
| Prepaid expenses and other current assets | 26,485 | 20,407 |
| Total current assets | 939,615 | 1,216,797 |
| Marketable securities - noncurrent | 164,013 | 69,338 |
| Property and equipment, net | 33,194 | 27,921 |
| Operating lease right-of-use assets | 123,550 | 133,076 |
| Equity method investment | 21,837 | 32,455 |
| Investments and other assets | 41,031 | 40,527 |
| Total Assets | 1,323,240 | 1,520,114 |
| Current Liabilities: | ||
| Accounts payable | 11,634 | 5,154 |
| Accrued expenses ($1.4 million and $1.6 million, respectively, from related party) | 49,534 | 60,876 |
| Current portion of operating lease liability | 16,750 | 16,685 |
| Current portion of deferred revenue ($2.9 million and $19.9 million, respectively, from related party) | 21,933 | 43,839 |
| Total current liabilities | 99,851 | 126,554 |
| Deferred revenue, net of current portion | 12,919 | 19,932 |
| Long-term operating lease liability | 105,582 | 114,018 |
| Contingent consideration liability | 0 | 24,026 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ Equity: | ||
| Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 88,347,634 and 87,103,007 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 9 | 9 |
| Additional paid-in capital | 2,512,741 | 2,420,223 |
| Accumulated other comprehensive loss | (3,868) | (7,461) |
| Accumulated deficit | (1,403,994) | (1,177,187) |
| Total stockholders’ equity | 1,104,888 | 1,235,584 |
| Total Liabilities and Stockholders’ Equity | $ 1,323,240 | $ 1,520,114 |
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.